Mottle Hyperpigmentation — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for mottle hyperpigmentation. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2038. Daily refresh.

1
Approved drugs
2
Active US patents
66/100
Avg vulnerability
—
Annual revenue covered

Originators in Mottle Hyperpigmentation

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bausch Health 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating mottle hyperpigmentation. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
38

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Retin-A
TRETINOIN
 Bausch Health 2 66 — 2038-08-22

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
11324710 Retin-A method of use 70 2038-08-22
10653656 Retin-A method of use 62 2038-08-22

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10653656 Retin-A method of use 62 2038-08-22
11324710 Retin-A method of use 70 2038-08-22

Related